Kevin Drum

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Today, LA Times columnist David Lazarus answers a question I’ve been curious about for some time: where do the generic names for drugs come from? For example, the two chemo drugs I take are Pomalyst™ and Darzalex™, aka pomalidomide and daratumumab. But where do those generic names come from?

The answer, it turns out, is two women who work for USAN, the United States Adopted Names program. Stephanie Shubat explains how they come up with generic names for pharmaceuticals:

Shubat said this is done primarily by assigning uniform “stems” to drug names — that is, drugs with similar structures or purposes will have similar-sounding names, or parts of their names. The anti-anxiety drug lorazepam, for instance, would share “azepam” with similar medications; cortisone derivatives would have “cort” somewhere in their generic name.

The artistry comes in the assignation of a prefix, Shubat said. Unlike with celecoxib, the prefix shouldn’t hark back to the name-brand drug. Nor should it be potentially offensive in any language….She also said USAN will put the kibosh on generic names that include the letters W, K, H, J and Y, because they could create confusion abroad for non-English speakers with different pronunciations….“Sometimes I look at license plates for new prefix ideas,” Shubat confided. “Sometimes I borrow from the names of cats or dogs.”

I figured out the “stem” part of this long ago, since similar drugs usually have identical stems. But I could never make any sense out of the stuff before that. I always figured it must have something to do with the specific chemical compound, but boy was I wrong. It comes from license plates and cat names. Yeesh.

However, I’m curious about Shubat’s claim that they no longer allow generic names that are too similar to the trademarked name. Take a look at the two chemo drugs I use. Both of them borrow the first three letters of the trademark name as the first three letters of the generic name. Apparently the pharmaceutical folks are trickier about getting their way than Shubat thinks.

WE'LL BE BLUNT:

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

WE'LL BE BLUNT

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate